UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
August 19, 2005
(Date of report)
CARACO PHARMACEUTICAL LABORATORIES, LTD.
(Exact name of registrant as specified in its charter)
|
Michigan |
|
0-24676 |
|
38-2505723 |
|
(State or other jurisdiction of incorporation) |
|
(Commission file number) |
|
(I.R.S. employer identification no.) |
1150 Elijah McCoy Drive, Detroit, Michigan 48202
(Address of principal executive offices)
(313) 871-8400
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12) |
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
On August 19, 2005, the Compensation Committee of the Board of Directors of registrant approved annual salaries (for fiscal year 2006, effective April 1, 2005) and eligibility for performance bonuses based on achievement of various criteria during fiscal year 2006 to its executive officers (other than the Chief Executive Officer) as follows:
|
Name |
Title |
Fiscal 2006 Salary |
Fiscal 2006 Performance Bonus Eligibility |
|
|
|
|
|
|
Jitendra N. Doshi |
CFO & COO |
$200,000 |
up to 30% of salary |
|
|
|
|
|
|
Robert Kurkiewicz |
Sr. V.P. - Technical |
$152,250 |
up to 23% of salary |
|
|
|
|
|
|
Gurpartap Singh Sachdeva |
V.P. – Sales & Marketing |
$175,500 |
up to 25% of salary |
Item 9.01. Financial Statements and Exhibits
|
c) |
Exhibits. |
|
Exhibit No. |
Description |
10.16 Summary of fiscal year 2006 executive officer salaries and performance bonus eligibility (other than the Chief Executive Officer).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CARACO PHARMACEUTICAL LABORATORIES, LTD.
|
|
Date: |
August 25, 2005 |
By: /s/
Daniel H. Movens Chief Executive Officer
|
|||
Exhibit Index
| 10.16 | Summary of fiscal year 2006 executive officer salaries and performance bonus eligibility (other than the Chief Executive Officer). |
2